Article Details
Retrieved on: 2021-04-22 11:03:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Biogen has announced new data for its multiple sclerosis therapies Tysabri and Vumerity, including analyses of extended interval dosing (EID) and ...
Article found on: www.pmlive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here